TrialThe Lancet. Oncology2018

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Jorge Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.